AR040498A1 - Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias - Google Patents

Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias

Info

Publication number
AR040498A1
AR040498A1 AR20030102585A ARP030102585A AR040498A1 AR 040498 A1 AR040498 A1 AR 040498A1 AR 20030102585 A AR20030102585 A AR 20030102585A AR P030102585 A ARP030102585 A AR P030102585A AR 040498 A1 AR040498 A1 AR 040498A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
aryl
halogen
heteroaryl
Prior art date
Application number
AR20030102585A
Other languages
English (en)
Inventor
Roger Victor Bonnert
Mark Dickinson
Rukhsana Rasul
Hitesh Sanganee
Simon John Teague
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR040498A1 publication Critical patent/AR040498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) o una sal aceptable para uso farmacéutico del mismo, donde: n representa 1 ó 2; R1 es uno o más sustituyentes seleccionados independientemente entre halógeno, CN, nitro, SO2R4, OR4, SR4, SOR4, SO2NR5R6, CONR5R6, NR5R6, NR9SO2R4, NR9CO2R4, NR9COR4, arilo, heteroarilo, alquenilo C2-6, alquinilo C2-6 o alquilo C1-6, estando los últimos cinco grupos optativamente sustituidos por uno o más sustituyentes seleccionados independientemente entre halógeno, OR8, y NR8R9, NR8R9, S(O)xR7 donde x es 0, 1 ó 2; R2 es hidrógeno, halógeno, CN, SO2R4, o CONR5R6, COR4 o alquilo C1-7, estando el último grupo optativamente sustituido por uno o más sustituyentes seleccionados independientemente entre átomos de halógeno, OR8 y NR5R6, S(O)xR7 donde x es 0, 1 ó 2; R3 es anillo o un anillo aromático de 5 a 7 miembros que contiene uno o más heteroátomos seleccionados entre N, S y O, cada uno de los cuales está optativamente sustituido por uno o más sustituyentes seleccionados independientemente entre halógeno, CN, nitro, SO2R4, OH, OR4, SR4, SOR4, SO2NR5R6, CONR5R6, NR5R6, NR9SO2R4, NR9CO2R4, NR9COR4, alquenilo C2-6, alquinilo C2-6, alquilo C1-6, estando los últimos tres grupos optativamente sustituidos por uno o más sustituyentes seleccionados independientemente entre átomos de halógeno, OR7, y NR8R9, S(O), R7 donde x es 0, 1 ó 2; R4 representa arilo, heteroarilo, o alquilo C1-6, todos los cuales pueden estar optativamente sustituidos por uno o más sustituyentes seleccionados independientemente entre átomos de halógeno, arilo, heteroarilo, OR10 y NR11R12S(O)xR13 (donde x = 0, 1 ó 2), CONR14R15, NR14COR15, SO2NR14R15, NR14SO2R15, CN, nitro; R5 y R6 representan independientemente un átomo de hidrógeno, un grupo alquilo C1-6, un arilo, o un heteroarilo, los últimos tres de los cuales pueden estar optativamente sustituidos por uno o más sustituyentes seleccionados independientemente entre átomos de halógeno, arilo, OR13 y NR14R15, CONR14R15, NR14COR15, SO2NR14R15, NR14SO2R15, CN, nitro; o R5 y R6 juntos con el átomo de nitrogeno al cual están unidos pueden formar un anillo heterocíclico saturado de 3 a 8 miembros que contiene optativamente uno o más átomos seleccionados entre O, S(O)x donde x es 0, 1 ó 2, NR16, y el anillo mismo está optativamente sustituido por alquilo C1-3; R7 y R13 representan independientemente un grupo alquilo C1-6, un arilo o heteroarilo todos los cuales pueden estar optativamente sustituidos por átomos de halógeno; R8 representa un átomo de hidrógeno, C(O)R9, alquilo C1-6 (optativamente sustituido por átomos de halógeno, grupos arilo o heteroarilo, ambos de los cuales pueden también estar optativamente sustituidos por uno o más átomos de flúor); un grupo arilo o heteroarilo, que puede estar optativamente sustituido por uno o más átomos de halógeno; cada uno de R9, R10, R11, R12, R14, R15, representa independientemente un átomo de hidrógeno, alquilo C1-6, un grupo arilo o heteroarilo (todos los cuales pueden estar optativamente sustituidos por uno o más átomos de halógeno); y R16 es hidrógeno, alquilo C1-4, -C(O)alquilo C1-4, C(O)Yalquilo C1-4, Y es O o NR7, o una sal aceptable para uso farmacéutico o solvato de la misma.
AR20030102585A 2002-07-17 2003-07-17 Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias AR040498A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202241A SE0202241D0 (sv) 2002-07-17 2002-07-17 Novel Compounds
SE0203713A SE0203713D0 (sv) 2002-07-17 2002-12-13 Novel compounds

Publications (1)

Publication Number Publication Date
AR040498A1 true AR040498A1 (es) 2005-04-06

Family

ID=30117585

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102585A AR040498A1 (es) 2002-07-17 2003-07-17 Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias

Country Status (23)

Country Link
US (2) US7723373B2 (es)
EP (1) EP1551802B1 (es)
JP (3) JP4791729B2 (es)
CN (1) CN1279023C (es)
AR (1) AR040498A1 (es)
AT (1) ATE450506T1 (es)
AU (1) AU2003251260B2 (es)
BR (1) BR0312729A (es)
CA (1) CA2492445A1 (es)
CY (1) CY1109760T1 (es)
DE (1) DE60330372D1 (es)
DK (1) DK1551802T3 (es)
ES (1) ES2335491T3 (es)
IL (1) IL166121A0 (es)
MX (1) MXPA05000646A (es)
NO (1) NO20050828L (es)
NZ (1) NZ537606A (es)
PT (1) PT1551802E (es)
SE (2) SE0202241D0 (es)
SI (1) SI1551802T1 (es)
TW (1) TW200404778A (es)
WO (1) WO2004007451A1 (es)
ZA (1) ZA200500170B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
AU2004259738B2 (en) * 2003-07-17 2011-11-17 Plexxikon, Inc. PPAR active compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005040114A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
DK1725553T3 (da) 2004-03-11 2008-08-18 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivater
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
MX2007002126A (es) * 2004-08-26 2007-09-14 Actelion Pharmaceuticals Ltd Derivados de acido 2-sulfanil-benzoimidazol-1-il-acetico como antagonistas de crth 2.
WO2006034419A2 (en) 2004-09-21 2006-03-30 Athersys, Inc. Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
PT1809602E (pt) * 2004-10-27 2008-12-15 Janssen Pharmaceutica Nv Derivados de indole úteis como moduladores do receptor da progesterona
WO2006056752A1 (en) 2004-11-23 2006-06-01 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
JP2008521831A (ja) * 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
EP1819673A2 (en) * 2004-11-30 2007-08-22 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
BRPI0519280A2 (pt) 2004-12-27 2009-01-06 Actelion Pharmaceuticals Ltd composto, composiÇço farmacÊutica e uso de um composto
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
CA2599348C (en) * 2005-02-25 2013-07-23 Ono Pharmaceutical Co., Ltd. Indole compound and use thereof
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
EP1916245B1 (en) 2005-07-22 2011-10-26 Shionogi & Co., Ltd. Indole derivative having pgd2 receptor antagonist activity
WO2007010965A1 (ja) 2005-07-22 2007-01-25 Shionogi & Co., Ltd. Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
RU2008108221A (ru) * 2005-09-07 2009-10-20 Плекссикон, Инк. (Us) Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
AU2006287528A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as PPAR active compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0526257D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2125722A2 (en) * 2006-05-26 2009-12-02 AstraZeneca AB Bi-aryl or aryl-heteroaryl substituted indoles
SI2037967T1 (sl) 2006-06-16 2017-04-26 The Trustees Of The University Of Pennsylvania Antagonisti receptorja za prostaglandin d2 za zdravljenje androgene alopecije
RU2458918C2 (ru) 2006-07-22 2012-08-20 Оксаген Лимитед Соединения, обладающие антагонистической активностью по отношению к crth2
CN101500996B (zh) 2006-08-07 2012-07-04 埃科特莱茵药品有限公司 (3-胺基-1,2,3,4-四氢-9h-咔唑-9-基)-乙酸衍生物
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
GB0722055D0 (en) * 2007-11-09 2007-12-19 Argenta Discovery Ltd Compounds
DK2229358T3 (da) 2007-12-14 2011-07-04 Pulmagen Therapeutics Asthma Ltd Indoler og deres terapeutiske anvendelse
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
RU2503672C2 (ru) 2008-01-18 2014-01-10 Оксаген Лимитед Соединения, обладающие активностью антагонистов crth2
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
EP2265581A1 (en) 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
CN102482214B (zh) 2009-07-06 2014-08-27 阿斯利康(瑞典)有限公司 制备4-(乙酰基氨基)-3-[(4-氯-苯基)硫基]-2-甲基-1h-吲哚-1-乙酸的中间体和方法
WO2011055270A1 (en) 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
AR079492A1 (es) 2009-12-23 2012-02-01 Ironwood Pharmaceuticals Inc Moduladores de crth2
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
SI2558447T1 (sl) 2010-03-22 2015-01-30 Actelion Pharmaceuticals Ltd. Derivati 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-karbazola in njihova uporaba kot modulatorji prostaglandinskega receptorja d2
RU2560147C2 (ru) 2010-06-21 2015-08-20 Оно Фармасьютикал Ко., Лтд. Новые кристаллические формы 4, 4'- [4-фтор-7({4-[4-(3-фтор-2-метилфенил)бутокси]фенил}этинил)-2-метил-1н-индол-1, 3-диил]дибутановой кислоты, 4, 4'-[2-метил-7-({4-[4-(пентафторфенил)бутокси] фенил}этинил)-1н-индол-1, 3-диил]дибутановой кислоты и 4, 4'-[4-фтор-2-метил-7-({4-[4-(2, 3, 4, 6-тетрафторфенил) бутокси]фенил}этинил)-1н-индол-1, 3-диил]дибутановой кислоты
JP5860459B2 (ja) 2010-06-30 2016-02-16 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激薬
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN103402515B (zh) 2010-11-09 2017-05-17 铁木医药有限公司 sGC刺激剂
BR112013026283A8 (pt) 2011-04-14 2018-01-30 Actelion Pharmaceuticals Ltd derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético e seu uso como moduladores do receptor d2 de prostaglandina
JP6054600B2 (ja) * 2011-08-11 2016-12-27 富士通コンポーネント株式会社 コネクタ
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
WO2013101830A1 (en) 2011-12-27 2013-07-04 Ironwood Pharmaceuticals, Inc. 2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators
EA033143B1 (ru) 2012-03-21 2019-09-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способ и применение селективного антагониста dp-2 по отношению к dp-1 для стимулирования роста волос
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2897953B8 (en) 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Sgc stimulators
RS59981B1 (sr) 2013-03-15 2020-03-31 Cyclerion Therapeutics Inc Sgc stimulatori
JP2016540017A (ja) 2013-12-11 2016-12-22 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激物質
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
AR099767A1 (es) 2014-03-17 2016-08-17 Actelion Pharmaceuticals Ltd Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2
CN106103437A (zh) 2014-03-18 2016-11-09 埃科特莱茵药品有限公司 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
CN107406421A (zh) 2014-09-17 2017-11-28 铁木医药有限公司 sGC刺激物
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
AU2015317824A1 (en) 2014-09-17 2017-03-23 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sGC stimulators
EP4420734A2 (en) 2015-02-13 2024-08-28 Institut National de la Santé et de la Recherche Médicale Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
WO2017019858A1 (en) 2015-07-30 2017-02-02 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2
US10351560B2 (en) 2015-09-15 2019-07-16 Idorsia Pharmaceuticals Ltd Crystalline forms
AU2017291826B2 (en) 2016-07-07 2021-10-21 Cyclerion Therapeutics, Inc. Phosphorus prodrugs of sGC stimulators
KR20230074840A (ko) 2016-07-07 2023-05-31 사이클리온 테라퓨틱스, 인크. sGC 자극제의 고체 형태
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US741360A (en) * 1899-11-13 1903-10-13 William M Moseley Toy.
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
NZ222878A (en) * 1986-12-17 1991-02-26 Merck Frosst Canada Inc 3-hetero-substituted-n-benzyl-indole derivatives, and pharmaceutical compositions
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
CA2079374C (en) * 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
PL175788B1 (pl) 1993-02-24 1999-02-26 Merck & Co Inc Amidowe pochodne indolu i zawierające je kompozycje farmaceutyczne
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
TW472045B (en) * 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
ZA987554B (en) 1997-08-21 2000-02-21 American Home Prod Methods for the solid phase synthesis of substituted indole compounds.
ZA9811672B (en) 1997-12-19 2000-06-19 Lilly Co Eli Hypoglycemic imidazoline compounds.
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU5886500A (en) 1999-06-23 2001-01-09 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
CA2699568C (en) 1999-12-24 2013-03-12 Aventis Pharma Limited Azaindoles
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
MXPA02012795A (es) * 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
PL370342A1 (en) * 2001-09-27 2005-05-16 F.Hoffmann-La Roche Ag Indole derivatives as cox ii inhibitors
US6933316B2 (en) * 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
JP4209332B2 (ja) 2002-02-01 2009-01-14 エフ．ホフマン−ラ ロシュ アーゲー α−１アゴニストとしての置換インドール
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
WO2005040114A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
EP2125722A2 (en) * 2006-05-26 2009-12-02 AstraZeneca AB Bi-aryl or aryl-heteroaryl substituted indoles
RU2008152763A (ru) 2006-06-08 2010-07-20 Ньюроки А/С (Dk) Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии
AU2007264114A1 (en) 2006-06-28 2008-01-03 Sanofi-Aventis New CXCR2 inhibitors

Also Published As

Publication number Publication date
EP1551802B1 (en) 2009-12-02
EP1551802A1 (en) 2005-07-13
SE0202241D0 (sv) 2002-07-17
MXPA05000646A (es) 2005-06-02
WO2004007451A1 (en) 2004-01-22
CY1109760T1 (el) 2014-09-10
US20100197756A1 (en) 2010-08-05
JP4791729B2 (ja) 2011-10-12
TW200404778A (en) 2004-04-01
IL166121A0 (en) 2006-01-15
CN1678579A (zh) 2005-10-05
SI1551802T1 (sl) 2010-03-31
CA2492445A1 (en) 2004-01-22
JP2010280680A (ja) 2010-12-16
JP2011116770A (ja) 2011-06-16
BR0312729A (pt) 2005-05-10
DE60330372D1 (de) 2010-01-14
AU2003251260B2 (en) 2007-04-26
PT1551802E (pt) 2010-02-02
US7723373B2 (en) 2010-05-25
JP2005537265A (ja) 2005-12-08
ATE450506T1 (de) 2009-12-15
NZ537606A (en) 2006-08-31
ES2335491T3 (es) 2010-03-29
SE0203713D0 (sv) 2002-12-13
AU2003251260A1 (en) 2004-02-02
US20060111426A1 (en) 2006-05-25
ZA200500170B (en) 2006-02-22
CN1279023C (zh) 2006-10-11
DK1551802T3 (da) 2010-03-15
NO20050828L (no) 2005-04-05

Similar Documents

Publication Publication Date Title
AR040498A1 (es) Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias
AR039934A1 (es) Indoles sustituidos para el tratamiento de desordenes respiratorios
AR045462A1 (es) DERIVADOS DE INDOLES SUSTITUIDOS eTILES COMO COMPUESTOS FARMACEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
AR044552A1 (es) Derivados del indol,composiciones farmaceuticas que los contienen y procesos para su preparacion, de utilidad para el tratamiento de trastornos respiratorios
AR039933A1 (es) Indoles sustituidos para tratamiento de desordenes respiratorios
ES2525763T3 (es) Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias
AR083686A2 (es) Compuestos de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-ona y uso en la fabricacion de medicamentos
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR045470A1 (es) Derivados de acido fenoxiacetico
AR036604A1 (es) Derivados de 4-pirimidona 3-sustituida
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR079541A1 (es) Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms
AR043199A1 (es) Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR035260A1 (es) Derivados de piperidina amino sustituidas, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de medicamentos como inhibidores de la gama secretasa, y para el tratamiento de la enfermedad de alzheimer
AR036659A1 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR051966A1 (es) Derivados de acido fenoxiacetico utiles para el tratamiento de enfermedades respiratorias
AR035325A1 (es) Derivados de adamantano, un proceso para su preparacion, composicion farmaceutica, un proceso para la preparacion de dicha composicion, y el uso de dichos derivados para la fabricacion de un medicamento
AR029805A1 (es) Compuestos heterociclicos, un proceso para su preparacion , intermediarios, composicion farmaceutica, un proceso para su preparacion, y el uso de dichos compuestos para la fabricacion de un medicamento
AR064889A1 (es) Derivados de piridopirimidinas, un metodo para su preparacion, una composicion y un producto farmaceutico que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por pde-4
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR020165A1 (es) Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal